# Personalized Compounded tirzepatide vs Zepbound® and Mounjaro®

Canonical page: https://bodienvi.com/blog/compounded-vs-brand-tirzepatide

Published September 22, 2026. Updated September 22, 2026. By Bodi Envi Clinical Content Team.

How compounded tirzepatide differs from Zepbound® and Mounjaro® in approval, oversight, packaging, evidence and price, as the labels and the FDA state it.

## Three products, one molecule

Tirzepatide reaches patients in three forms. Zepbound® and Mounjaro® are FDA-approved products made by one manufacturer for different approved uses. Personalized Compounded tirzepatide is the same molecule prepared by a compounding pharmacy for an individual prescription, and it is what Bodi Envi's tirzepatide programs may include when a licensed provider prescribes it. People compare the three mostly on price, but the price follows from a set of differences that come first: approval, oversight, packaging, evidence and what the FDA has said. This guide takes them in that order, as the product labels and the FDA state them.

This is general information and not medical advice. Personalized Compounded tirzepatide is not FDA-approved and is not equivalent to Zepbound® or Mounjaro®. Brand names are trademarks of their respective owners and Bodi Envi is not affiliated with them. Your licensed provider is the person to ask about which, if any, is appropriate for you.

## What each branded product is approved for

The prescribing information is the FDA-approved statement of what a product is for. The Zepbound® label says it is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. The Mounjaro® label says it is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children aged ten and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk of them.

The Zepbound® label adds that coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. Both labels open with the same boxed warning about thyroid C-cell tumours seen in rat studies, carry the same contraindications, and list the same set of warnings about pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications in people with type 2 diabetes and aspiration during anaesthesia.

The weight management indication belongs to Zepbound®. Mounjaro® is the same molecule approved for a different condition, which is why it is not the natural comparison for a weight management program and why the cost figures below lead with Zepbound®.

## Approval and review

Zepbound® and Mounjaro® went through FDA approval. Their manufacturer ran the trials, submitted the data, and had the formulation, manufacturing and labelling reviewed before either product went on sale. The labels quoted above are FDA-approved documents.

Personalized Compounded tirzepatide has been through none of that. The FDA's human drug compounding page states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. The FDA's questions and answers page adds that a compounded drug is not a generic, because a generic is approved under the law and has been found equivalent to the brand, and that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Bodi Envi states the consequence directly: personalized compounded tirzepatide is not FDA-approved and is not equivalent to FDA-approved products.

Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.

At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

## Who makes it and who oversees them

The branded products are manufactured at scale in facilities the FDA inspects, under current good manufacturing practice requirements.

Personalized Compounded tirzepatide is made by a compounding pharmacy for one patient. According to the FDA's questions and answers page, state boards of pharmacy generally have primary responsibility for the day to day oversight of state-licensed pharmacies operating under section 503A of the federal law, which must compound on the basis of a patient-specific prescription and are not subject to current good manufacturing practice requirements, while outsourcing facilities registered under section 503B are primarily overseen and inspected by the FDA and are subject to those requirements. Bodi Envi's prescriptions go to third party U.S. 503A licensed compounding pharmacies, and Bodi Envi publishes that applicable state boards of pharmacy regulate and inspect them and that their sterile compounding practices are subject to applicable U.S. Pharmacopeia standards. VialsRx is the current pharmacy partner for applicable GLP-1 prescriptions; availability may vary by program and patient location, and the prescription label confirms the pharmacy that applies to your treatment.

## Pens, vials and measuring

The Zepbound® label describes the product as a single-dose pen, a single-dose vial and a single-patient-use multi-dose pen, and the Mounjaro® label describes the same presentations. In each case the dose is set by the strength of the device, and the device was part of what the FDA reviewed. The labels also describe what the escalation looks like: a starting dose of 2.5 mg once weekly for four weeks, then 5 mg, then increases of 2.5 mg after at least four weeks on a dose, with 5 mg, 10 mg and 15 mg as the maintenance doses for weight reduction and 15 mg as the maximum, all to reduce the risk of gastrointestinal adverse reactions. That is a description of the approved product, not advice.

Personalized Compounded tirzepatide typically comes as a vial of solution to be measured with a syringe, though the presentation depends on the pharmacy, and the concentration can differ between pharmacies and from the branded products. The FDA's statement on unapproved GLP-1 drugs, dated September 1, 2026, reports adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide, and adverse events in patients prescribed personalized compounded semaglutide or tirzepatide in doses beyond what the approved label describes. It asks providers to be vigilant about dosing and titration and encourages patients to talk with their provider or the compounder about how to measure the intended dose. With a compounded prescription, the pharmacy's measuring instructions and your care team's plan govern, and no dose should be changed on your own.

Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.

At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

## Storage

The two branded labels give the same storage rules, which are a useful reference for what the molecule needs even though the pharmacy label for a compounded vial is the one to follow. Both say to store the single-dose pen or vial in the refrigerator between 36°F and 46°F, that if needed it may be kept unrefrigerated at up to 86°F for a total of 21 days and then discarded, that the product must be protected from heat and light and kept in its carton, and that it must not be frozen or used if it has been frozen. The FDA adds that it has received complaints of compounded GLP-1 drugs arriving warm or with inadequate ice packs, and recommends not using any injectable GLP-1 drug that arrives warm. The storage and travel guides on this site cover this in more depth.

Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.

At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

## Evidence

The reference trial for tirzepatide in weight management is SURMOUNT-1, published by Jastreboff and colleagues in the New England Journal of Medicine in 2022. According to the abstract on PubMed, 2,539 adults with obesity or overweight and no diabetes took 5 mg, 10 mg or 15 mg of tirzepatide or placebo once weekly for 72 weeks; the mean change in weight was 15.0, 19.5 and 20.9 percent with the three doses against 3.1 percent with placebo, and the most common adverse events were gastrointestinal, mostly mild to moderate and occurring mainly during dose escalation. The Zepbound® label reports that trial and others, including its obstructive sleep apnea studies, and gives the frequencies of side effects seen.

SURMOUNT-1 studied Zepbound®. No trial of comparable size has studied personalized compounded tirzepatide, and the FDA notes that pharmacies operating under 503A are not required by federal law to report adverse events to the agency, so what is known about compounded products comes from fewer and less systematic reports. The label figures are evidence about the approved product; whether they carry over to a compounded vial has not been shown. Individual experiences and outcomes vary.

Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.

At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

## What the FDA says to watch for

The FDA's statement lists warning signs of an unsafe seller of GLP-1 drugs: a claim that the compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, medicine that looks different from a previous fill or arrives damaged or without instructions, no screening and prescription by a licensed doctor, no licensed doctor available afterwards, spelling errors or wrong addresses on the label, and a pharmacy name that may be fraudulent. It reports fraudulent products labeled with the names of pharmacies that do not exist or did not make them, including one adverse event report involving a product labelled as personalized compounded tirzepatide from a pharmacy that did not compound it. Its recommendations are a prescription from a licensed provider, filled at a state-licensed pharmacy.

## Price, as of September 2026

The brand figures come from Lilly's own pricing information pages, checked in September 2026. Lilly defines a list price as the wholesale acquisition cost, the price at which it sells to wholesalers, says the amount a patient pays largely depends on their insurance plan, and defines a fill as a 28 day month of up to four pens. Bodi Envi's figures come from its Plans page.

| Product | Published price | Source |
| --- | --- | --- |
| Zepbound® | $499 to $1,086.37 per fill, list price, as of September 2026 | Lilly pricing information |
| Zepbound® KwikPen® or vial, self pay | from $299 per month at 2.5 mg, rising by dose, as of September 2026 | Lilly savings page |
| Mounjaro® | $1,112.16 per fill, list price, as of September 2026 | Lilly pricing information |
| Bodi Envi personalized compounded tirzepatide, monthly | $229 per month, billed monthly | Bodi Envi Plans page |
| Bodi Envi, 3 month plan | $219 per month, $657 paid once | Bodi Envi Plans page |
| Bodi Envi, 6 month plan | $205 per month, $1,230 paid once | Bodi Envi Plans page |
| Bodi Envi, 12 month plan | $175 per month, $2,100 paid once | Bodi Envi Plans page |

Two notes on reading it. The Zepbound® list figure is a range because the product comes in several presentations, and Lilly's savings page publishes a self pay price for the vial and KwikPen® that starts at $299 for a one month supply at the 2.5 mg dose and rises with dose, along with a savings card for commercially insured patients; those programs carry their own terms and end dates, and the tirzepatide cost guide on this site sets them out in full. And Bodi Envi's price is a program price, the same at every dose, that includes the assessment, provider review, messaging with the care team, a GLP-1 ebook and diet plan, and the medication when prescribed, whereas a list price covers the medication alone.

The gap is a consequence of everything above. A compounded product has not been through FDA review, is prepared by a pharmacy for one patient rather than manufactured at scale, and is measured by the patient from a vial. The lower price is not a discount on Zepbound®; it is a different thing.

## How Bodi Envi's program approaches it

Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer, and it does not sell, supply or represent branded medications. Clinical services for applicable programs are provided by Wasef Health, PC, whose licensed providers independently decide whether treatment is appropriate. Prescriptions are dispensed by third party U.S. 503A licensed compounding pharmacies.

For applicable programs, pricing does not increase based solely on dosage strength, and medication is included only when a licensed healthcare provider determines treatment is medically appropriate and issues a prescription. Completing an assessment does not guarantee one. Whether personalized compounded tirzepatide, a branded product or neither is right for you is your provider's decision; this guide is general information, the trial cited studied the branded product, and your provider is the person to ask.

## Frequently asked questions

### Is personalized compounded tirzepatide the same as Zepbound®?

No. Zepbound® is an FDA-approved product made by its manufacturer and reviewed before sale. Personalized Compounded tirzepatide is prepared by a licensed pharmacy for one patient's prescription, is not FDA-approved, is not reviewed by the FDA for safety, effectiveness or quality before it is marketed, and is not equivalent to Zepbound® or Mounjaro®. The two share an active ingredient and differ in nearly everything else. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

### What is the difference between Zepbound® and Mounjaro®?

Both contain tirzepatide and come from the same manufacturer. Per their prescribing information, Zepbound® is approved for weight reduction and long term maintenance in adults with obesity or overweight and a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro® is approved to improve blood sugar control in type 2 diabetes and to reduce certain cardiovascular risks in that population.

### How is personalized compounded tirzepatide dispensed?

Typically, as a vial of solution measured with a syringe, though the presentation depends on the pharmacy. The branded products come as single-dose pens and vials and a multi-dose pen with the dose set by the device. The FDA has reported adverse events linked to dosing errors with compounded GLP-1 products, so following the pharmacy's measuring instructions exactly matters.

### What do the branded products cost?

As of September 2026, Lilly's own pricing information pages give the list price of Zepbound® as $499 to $1,086.37 per fill depending on presentation and Mounjaro® as $1,112.16 per fill, with a fill defined as a 28 day month. Lilly also publishes savings and self pay prices below list that carry their own terms.

### What does Bodi Envi's personalized compounded tirzepatide program cost?

The Plans page publishes $229 per month billed monthly, $219 per month on a three month plan, $205 on a six month plan and $175 on a twelve month plan, the same at every dose, including the assessment, provider review, care team messaging, a GLP-1 ebook and diet plan, and the medication when a provider prescribes it. Completing an assessment does not guarantee a prescription.

### Who should choose which?

A licensed provider, with your health history in front of them. The FDA's position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. This guide sets out the differences so you can ask informed questions, not so you can decide alone.

## Sources

- Zepbound® (tirzepatide) injection prescribing information, DailyMed, revised August 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (checked September 2026)
- Mounjaro® (tirzepatide) injection prescribing information, DailyMed, revised August 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 (checked September 2026)
- Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022, PubMed: https://pubmed.ncbi.nlm.nih.gov/35658024/ (checked September 2026)
- FDA, Human Drug Compounding: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding (checked September 2026)
- FDA, Compounding and the FDA, Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (checked September 2026)
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, dated September 1, 2026: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (checked September 2026)
- Lilly, Zepbound® cost information: https://pricinginfo.lilly.com/zepbound (checked September 2026)
- Lilly, Mounjaro® cost information: https://pricinginfo.lilly.com/mounjaro (checked September 2026)
- Lilly, Zepbound® savings and self pay options: https://zepbound.lilly.com/savings (checked September 2026)
- Bodi Envi plans and pricing: https://bodienvi.com/plans (checked September 2026)